

The management of venous thromboembolic diseases and the role of thrombophilia testing

Minutes: Final

Guideline Development Group Meeting **2nd GDG meeting**

Date and Time: **21st July 2010, 10:30 – 16.00pm**

Place: *National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ*

Present:

Gerard Stansby (Chair) (GS)	(Present for notes 1 – 8)
Roshan Agarwal (RA)	(Present for notes 1 – 8)
David Berridge (DB)	(Present for notes 1 – 8)
Christian Clark (CC)	(Present for notes 1 – 8)
Richard Day (RD)	(Present for notes 1 – 8)
Scott Harrison (SH)	(Present for notes 1 – 8)
David Keeling (DK)	(Present for notes 1 – 8)
Nigel Langford (NL)	(Present for notes 1 – 8)
Steven Moser (SM)	(Present for notes 1 – 8)
Karen Sheares (KS)	(Present for notes 1 – 8)

NCGC Present:

Clare Jones (CJ)	(Present for notes 1 – 8)
Jennifer Hill (JH)	(Present for notes 1 – 8)
Lee-Yee Chong (LC)	(Present for notes 1 – 8)
Elisabetta Fenu (EF)	(Present for notes 1 – 8)
Sarah Riley (SR)	(Present for notes 1 – 8)
Julie Neilson (JN)	(Present for notes 1 – 8)

In attendance:

NICE Staff:	Sarah Dunsdon	(Present for notes 1 – 8)
-------------	---------------	---------------------------

Observers:

NCGC Staff:	Serena Carville Grammati Sarri Vanessa Nunes	(Present for notes 1 – 8) (Present for notes 7) (Present for notes 7)
-------------	--	---

Agenda Item:

- 1. Introductions and apologies for absence:** GS welcomed the group to the second meeting of this GDG. Apologies were received from Paul Mainwaring, Kat Noble, Hayley Flavell and Beverley Hunt.

Declarations of Interest: GS asked for each GDG member to declare their interests verbally. Each GDG members declared his/her interests in front of all those present.

Agenda Item:

GDG members:

DK declared a personal pecuniary interest; he received a lecture fee (17th November 2009) for an education meeting sponsored by Bayer for haematology trainees. He received a fee for attending an advisory board on the 19th February 2010 on haemophilia from Wyeth. He received a lecture fee from Boehringer-Ingelheim on the 25th March 2010 for staff training. He declared that he knew of no personal family interests. He declared a non-personal pecuniary interest; Boehringer-Ingelheim sponsors their department research nurse. He declared a personal non-pecuniary interest; he is the UK Chief Investigator for the Re-COVER, RE-COVER 2 and RE-MEDY trials of dabigatran etexilate (Boehringer-Ingelheim) in VTE.

SM declared that he knew of no personal pecuniary interest, personal family interest, non-personal pecuniary interest or personal non-pecuniary interest.

GS, RA, DB, CC, RD, SH, NL and KS declared that they knew of no personal pecuniary interest, personal family interest, non-personal pecuniary interest or personal non-pecuniary interest, above those declared at the previous meeting.

NCGC members: CJ, EF, SR, LC, JH and JN declared that they knew of no personal pecuniary interest, personal family interest, non-personal pecuniary interest and personal non-pecuniary interest.

No actions were taken following these declarations as they were not considered to be a conflict of interest warranting their withdrawal from the meeting.

Minutes of the last meeting: The minutes of the last meeting were reviewed by the group and accepted as an accurate record.

2. **Cancer screening for patients with spontaneous VTE:** LYC presented a summary of the clinical and economic evidence for this review question.
3. **Economic plan:** EF presented the draft economic plan.
4. **Background to diagnostic tests:** GS presented an overview of diagnostic tests for detecting pulmonary embolism.
5. **Summary of validated algorithms and V/Q scans:** LYC and CJ presented a summary of the search results for these questions.
6. **Clarifying PICO questions:** The GDG members continued to work on refining and defining the review questions.
7. **Initial Assessment of pulmonary embolism by CT:** SR and EF presented the clinical and economic evidence for this review question.
8. **Any other business:** There was no other business to discuss.

Date, time and venue of the next meeting

3rd GDG, Thursday 9th September 2010, 10.30-16.00, at National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ.